Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 0.80 |
| ▸ | ADRB1 | P08588 | 19/20 | 0.80 |
| ▸ | ADRB3 | P13945 | 19/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | HTR1A | P08908 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | HTR1B | P28222 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL265153 | 1.00 | ADRB2 (0.80) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL265152 | 1.00 | ADRB2 (0.80) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL29390360 | 1.00 | ADRB2 (0.80) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL5283973 | 0.89 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL266486 | 0.89 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL266487 | 0.89 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL4807879 | 0.88 | ADRB2 (0.84) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL3616766 | 0.88 | ADRB2 (0.60) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL4807888 | 0.88 | ADRB2 (0.84) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL5116485 | 0.87 | ADRB2 (0.97) | ADRB2ADRB1ADRB3CYP3A4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179019-A1 | CRYSTALLINE FREEBASE FORMS OF A BIPHENYL COMPOUND | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2025-06-05 | — | — | US | disclosed |
| US-20190262376-A1 | COMPOSITIONS COMPRISING ANTISENSE-ENCODED ERYTHROPOIETIN RECEPTOR AND USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-08-29 | — | — | US | disclosed |
| EP-1370521-B1 | FORMANILIDE DERIVATIVES AS BETA2-ADRENORECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2007-12-19 | — | — | EP | disclosed |
| EP-1723108-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| US-7045658-B2 | prophylaxis and treatment of respiratory diseases; phenethanolamine derivatives | GLAXO GROUP LIMITED (GB) | 2006-05-16 | — | — | US | disclosed |
| EP-1633707-A1 | 1- (ALKYLAMINOALKYL-PYROLIDIN-/PIPERIDINYL) -2, 2-DIPHENYLACETAMIDE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1592685-A1 | BIPHENYL DERIVATIVES HAVING &bgr; sb 2 /sb ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | Theravance Inc (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2005087733-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005003090-A1 | 1- (ALKYLAMINOALKYL-PYROLIDIN-/PIPERIDINYL) -2, 2-DIPHENYLACETAMIDE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| WO-2004074276-A1 | BIPHENYL DERIVATIVES HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040157830-A1 | Formailide derivatives as beta2-adrenoreceptor agonists | GLAXO GROUP LIMITED (GB) | 2004-08-12 | — | — | US | disclosed |
| EP-1370521-A1 | FORMANILIDE DERIVATIVES AS BETA2-ADRENORECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002076933-A1 | FORMAILIDE DERIVATIVES AS BETA2-ADRENORECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157830-A1 | Formailide derivatives as beta2-adrenoreceptor agonists | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885ADRB1 2/4885ADRB3 7/4885 |
| US-20250179019-A1 | CRYSTALLINE FREEBASE FORMS OF A BIPHENYL COMPOUND | TBCB, FFAR1, CRYAB | ADRB2 1997/4885ADRB1 865/4885ADRB3 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.